{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:05:27Z","timestamp":1779797127549,"version":"3.53.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.therap.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:59:48Z","timestamp":1778169588000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2405-4778","authenticated-orcid":false,"given":"Jennifer","family":"Lagoutte-Renosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Blanche","family":"Valnet Rabier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Berbescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Bozon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Ursenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gantner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Lepiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Montange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Davani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Muret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.04.006_bib0055","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/jac\/dkx461","article-title":"Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid","volume":"73","author":"Palazzo","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2026.04.006_bib0060","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1097\/QAD.0000000000002256","article-title":"Drug interactions are not always predictable: the curious case of valproic acid and dolutegravir and a possible explanation","volume":"33","author":"Tseng","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2026.04.006_bib0065","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkaa094","article-title":"Antiretroviral concentrations in the presence and absence of valproic acid","volume":"75","author":"Calcagno","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2026.04.006_bib0070","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/jac\/dkab021","article-title":"The dolutegravir\/valproic acid drug-drug interaction is primarily based on protein displacement","volume":"76","author":"Bollen","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2026.04.006_bib0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/FTD.0000000000001221","article-title":"Management of the drug-drug interactions between valproic acid and dolutegravir-a case study","volume":"46","author":"Cattaneo","year":"2024","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2026.04.006_bib0080","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-020-00898-8","article-title":"Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: An updated review","volume":"59","author":"Podany","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2026.04.006_bib0085","doi-asserted-by":"crossref","first-page":"e00895","DOI":"10.1128\/AAC.00895-20","article-title":"Characteristics of dolutegravir and bictegravir plasma protein binding: a first approach for the study of pharmacologic sanctuaries","volume":"64","author":"Gel\u00e9","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.therap.2026.04.006_bib0090","unstructured":"CNS. Recommandations de prise en charge du VIH, des h\u00e9patites virales et des IST\u00a0: rapport d\u2019experts. February 2025. https:\/\/cns.sante.fr\/dossiers\/dossier-experts\/rapport-experts-2023\/ [Accessed 30 April 2026]."},{"key":"10.1016\/j.therap.2026.04.006_bib0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.therap.2026.04.006_bib0100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/clpt.1980.235","article-title":"Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects","volume":"28","author":"Perucca","year":"1980","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:16:06Z","timestamp":1779794166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"alternative-id":["S0040595726000636"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.04.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}